Program
Cetylpyridinium
Also written as “Cetylpyridinium chloride”, “Cetylpyridinium Chloride (CPC) and Zinc Lactate Mouthwash” and “cetylpyridinium chloride (CPC), zinc lactate and sodium fluoride Mouthwash”.
Its studies are mostly in Gingivitis · Dental Plaque · Pharyngitis · Diabetes Mellitus, Type 2 · Onychomycosis, led by 7 companies.
Drug pageCetylpyridinium: every studyMany companies study it; this page follows only the 15 they lead. All 27 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Colgate Palmoliveits history only | 61 open or running | phase 4since Feb 6, 2015 | Jul 15, 2014 | Jan 2, 2028phase 4 · NCT07619729 |
| Procter and Gambleits history only | 20 open or running | phase 4since Sep 29, 2025 | Feb 28, 2012 | none ahead |
| Sanofiits history only | 20 open or running | phase 3since May 27, 2008 | May 27, 2008 | none ahead |
| Valenta Pharm JSC | 22 open or running | phase 1since Feb 17, 2025 | Feb 17, 2025 | Dec 1, 2026phase 1 · NCT06859281 |
| Angelini Pharmaits history only | 10 open or running | phase 1since Apr 27, 2018 | Apr 27, 2018 | none ahead |
| NanoBioits history only | 10 open or running | phase 2since Mar 26, 2007 | Mar 26, 2007 | none ahead |
| Suzhou Neologics Bioscienceits history only | 11 open or running | phase 1since May 25, 2023 | May 25, 2023 | none ahead |
Also a collaborator on its studies: Cross Research.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Valenta Pharm JSC only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 17, 2025First studies: 2 phase 1 studies in PharyngitisFirst studyNCT06859281, NCT06857890
Ahead
- Dec 1, 2026Primary completion: phase 1 study in PharyngitisNCT06859281
- Dec 1, 2026Primary completion: phase 1 study in PharyngitisNCT06857890
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 Valenta Pharm JSC leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06859281Pharyngitis · Russia | 1 | Recruiting | Dec 1, 2026 | 24 |
| NCT06857890Pharyngitis · Russia | 1 | Recruiting | Dec 1, 2026 | 24 |
How it is read
Names in the registry
- “Cetylpyridinium chloride”, 2 entries
- “Cetylpyridinium Chloride (CPC) and Zinc Lactate Mouthwash”, 1 entry
- “cetylpyridinium chloride (CPC), zinc lactate and sodium fluoride Mouthwash”, 1 entry
- “Cetylpyridinium Chloride, Zinc Lactate and Hyaluronic Acid Mouthwash”, 1 entry
- “Cetylpyridinium Chloride (CPC)”, 1 entry
Conditions, from the studies’ own filings
- Gingivitis, 4 studies
- Dental Plaque, 3 studies
- Pharyngitis, 2 studies
- Diabetes Mellitus, Type 2, 1 study
- Onychomycosis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.